Publications

Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma.
Oncol Rep 2018 Feb 29;39(2):455-464. Epub 2017 Nov 29.
Morgan Adams Foundation Pediatric Brain Tumor Research Program, University of Colorado School of Medicine, Aurora, CO 80045, USA.

NF-κB upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma.
Neuro Oncol 2017 Oct;19(10):1350-1360
Department of Pediatrics, University of Colorado Denver, Aurora, Colorado; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado; Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado; Department of Neurosurgery, University of Colorado Denver, Aurora, Colorado.


Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood.
J Neuropathol Exp Neurol 2017 Jul;76(7):595-604
Morgan Adams Foundation Pediatric Brain Tumor Research Program; Department of Pathology; and Department of Neurosurgery, University of Colorado Anschutz Medical Campus; and Children's Hospital Colorado, Aurora, Colorado.

Intertumoral Heterogeneity within Medulloblastoma Subgroups.
Cancer Cell 2017 Jun;31(6):737-754.e6
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada; Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada. Electronic address:

Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma.
Oncotarget 2016 Aug;7(33):53881-53894
Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.

A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.
ACS Chem Biol 2016 Apr 8;11(4):921-30. Epub 2016 Jan 8.
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , 12850 East Montview Boulevard, V20-2102, Aurora, Colorado 80045, United States.

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.
Lancet Oncol 2016 Apr 12;17(4):484-495. Epub 2016 Mar 12.
Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. Electronic address:

Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma.
Cancer Immunol Res 2015 Oct 12;3(10):1165-74. Epub 2015 May 12.
Department of Pediatrics, University of Colorado Denver, Aurora, Colorado. Children's Hospital Colorado, Aurora, Colorado. Department of Neurosurgery, University of Colorado Denver, Aurora, Colorado.


Cytogenetic prognostication within medulloblastoma subgroups.
J Clin Oncol 2014 Mar 3;32(9):886-96. Epub 2014 Feb 3.
David J.H. Shih, Marc Remke, Vijay Ramaswamy, Betty Luu, Yuan Yao, Xin Wang, Adrian M. Dubuc, Livia Garzia, John Peacock, Stephen C. Mack, Xiaochong Wu, Adi Rolider, A. Sorana Morrissy, Florence M.G. Cavalli, Claudia C. Faria, Stephen W. Scherer, Uri Tabori, Cynthia E. Hawkins, David Malkin, Eric Bouffet, James T. Rutka, and Michael D. Taylor, Hospital for Sick Children; David J.H. Shih, Marc Remke, Vijay Ramaswamy, Yuan Yao, Xin Wang, Adrian M. Dubuc, John Peacock, Stephen C. Mack, and Michael D. Taylor, University of Toronto, Toronto; Boleslaw Lach, McMaster University, Hamilton, Ontario; Jennifer A. Chan, University of Calgary, Calgary, Alberta; Steffen Albrecht, Adam Fontebasso, and Nada Jabado, McGill University, Montreal, Quebec, Canada; Paul A. Northcott, Andrey Korshunov, Marcel Kool, David T.W. Jones, and Stefan M. Pfister, German Cancer Research Center; Stefan M. Pfister, University Hospital Heidelberg, Heidelberg; Ulrich Schüller, Ludwig-Maximilians-University, Munich; Stefan Rutkowski, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Karel Zitterbart, Masaryk University School of Medicine; Karel Zitterbart and Leos Kren, University Hospital Brno, Brno, Czech Republic; Toshihiro Kumabe and Teiji Tominaga, Tohoku University Graduate School of Medicine, Sendai, Japan; Young Shin Ra, University of Ulsan, Asan Medical Center; Ji-Yeoun Lee, Byung-Kyu Cho, Seung-Ki Kim, and Kyu-Chang Wang, Seoul National University Children's Hospital, Seoul; Shin Jung, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Chonnam, South Korea; Peter Hauser and Miklós Garami, Semmelweis University, Budapest; László Bognár and Almos Klekner, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary; Shenandoah Robinson, Boston Children's Hospital; Scott L. Pomeroy, Harvard Medical School, Boston, MA; Ali G. Saad, University of Arkansas for Medical Sciences, Little

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.
Mol Cancer 2014 Mar 24;13:72. Epub 2014 Mar 24.
Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, 12800 E 19th Ave, Mail Stop 8302, Aurora, CO, 80045, USA.

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.
Acta Neuropathol 2013 Dec 31;126(6):917-29. Epub 2013 Oct 31.
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.



Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Neuro Oncol 2013 Feb 28;15(2):149-60. Epub 2012 Nov 28.
Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children’s Hospital Colorado, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado 80045, USA.

Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells.
J Neurooncol 2013 Jan 9;111(2):113-21. Epub 2012 Nov 9.
Department of Pediatrics, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.

MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma.
J Biol Chem 2013 Jan 4;288(3):1918-28. Epub 2012 Dec 4.
Department of Pediatrics, Children’s Hospital Colorado, University of Colorado, Denver, Colorado 80045, USA.

Subgroup-specific structural variation across 1,000 medulloblastoma genomes.
Nature 2012 Aug;488(7409):49-56
Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario M5G 1L7, Canada.

Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
BMC Cancer 2012 Mar 5;12:80. Epub 2012 Mar 5.
Department of Pediatrics and Children's Hospital Colorado, University of Colorado Denver, Anschutz Medical Campus, Aurora, USA.


Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma.
Cancer Res 2006 Jul;66(13):6665-74
Neurogenomic Research Laboratory, Department of Neurosurgery, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.


Combined EphB2 receptor knockdown with radiation decreases cell viability and invasion in medulloblastoma.
Cancer Cell Int 2017 29;17:41. Epub 2017 Mar 29.
Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, 1665 Aurora Court Suite 1032, Aurora, CO 80045 USA.

OF